Obiettivo Over the past 10 years DNA sequencing has revolutionized how we apply genetics in personalized healthcare, diagnosis and drug development despite that the sequencing technology comes with numerous shortcomings. Samplix has developed a proprietary technology, Xdrop™, which addresses these shortcomings. Samplix’ technology encompasses state of the art microfluidics, molecular biology and bioinformatics. The Xdrop technology enables scientists and medical personnel to retrieve specific single DNA molecules from a minute amount of biological sample e.g. tumour biopsies, for subsequent DNA sequencing. At the core of the Xdrop technology is the generation of millions of droplets, each droplet constituting a reaction chamber for the sample preparation of single DNA molecules. This is opposed to today’s technology which is based on bulk preparation of sample material for DNA sequencing.Single molecule resolution is key to understanding the complexity of major diseases such as cancer, immunological diseases, mental disorders, etc. The proposed project addresses the need to qualify known market barriers and put measures in place to overcome such market barriers. Samplix has engaged a very experienced management team with an aggregated experience of >50 years in developing and selling products for DNA analysis. Samplix has already established: • 5 test site agreements with leading DNA institutions around the globe• Agreements with leading OEM providers on instrument and consumables• A patent estate of 5 patent families. • Freedom to operate in multibillion € market.At Samplix, we strive at 100 mUSD in revenue and profitability in year five after full commercial launch. To achieve such an ambitious goal, we plan to apply a razor/razor blade sales strategy by installing the instrument “for free” in return for a subscription to consumables Samplix raised 4,5 m€ in May 2018 which brings the total capital raised to 8 m€. A bigger financing round is planned for 2019. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidicsmedical and health sciencesclinical medicinepsychiatrynatural sciencesbiological sciencesgeneticsDNAnatural sciencesbiological sciencesmolecular biology Programma(i) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Argomento(i) EIC-SMEInst-2018-2020 - SME instrument Invito a presentare proposte H2020-EIC-SMEInst-2018-2020 Vedi altri progetti per questo bando Bando secondario H2020-SMEInst-2018-2020-2 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore SAMPLIX ApS Contribution nette de l'UE € 1 868 736,63 Indirizzo BREGNERODVEJ 96 3460 Birkerod Danimarca Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Danmark Hovedstaden Nordsjælland Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 669 623,75